US20030009158A1 - Skin treatments using blue and violet light - Google Patents
Skin treatments using blue and violet light Download PDFInfo
- Publication number
- US20030009158A1 US20030009158A1 US09/901,847 US90184701A US2003009158A1 US 20030009158 A1 US20030009158 A1 US 20030009158A1 US 90184701 A US90184701 A US 90184701A US 2003009158 A1 US2003009158 A1 US 2003009158A1
- Authority
- US
- United States
- Prior art keywords
- light
- skin
- blue
- areas
- violet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title description 13
- 210000003491 skin Anatomy 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 230000032683 aging Effects 0.000 claims abstract description 16
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940061720 alpha hydroxy acid Drugs 0.000 claims abstract description 8
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims abstract description 8
- 230000001678 irradiating effect Effects 0.000 claims abstract description 4
- 210000000434 stratum corneum Anatomy 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims description 11
- 230000003287 optical effect Effects 0.000 claims description 3
- 239000007933 dermal patch Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 230000001427 coherent effect Effects 0.000 abstract description 3
- 230000035515 penetration Effects 0.000 abstract description 2
- 244000172533 Viola sororia Species 0.000 description 22
- 230000008901 benefit Effects 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000001126 phototherapy Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000000542 fatty acid esters of ascorbic acid Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- -1 hydroxyl radicals Chemical class 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 244000154870 Viola adunca Species 0.000 description 3
- 235000005811 Viola adunca Nutrition 0.000 description 3
- 235000013487 Viola odorata Nutrition 0.000 description 3
- 235000002254 Viola papilionacea Nutrition 0.000 description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000004261 Ascorbyl stearate Substances 0.000 description 2
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000019276 ascorbyl stearate Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 230000003960 inflammatory cascade Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000007114 proinflammatory cascade Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 102100024335 Collagen alpha-1(VII) chain Human genes 0.000 description 1
- 101710096484 Collagen alpha-1(VII) chain Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- DWKSHXDVQRZSII-SUMWQHHRSA-N [(2s)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DWKSHXDVQRZSII-SUMWQHHRSA-N 0.000 description 1
- MSKSZMDNKAEBSG-HNAYVOBHSA-N [(2s)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O MSKSZMDNKAEBSG-HNAYVOBHSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940116224 behenate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000010413 gardening Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 235000021178 picnic Nutrition 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D31/00—Materials specially adapted for outerwear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0616—Skin treatment other than tanning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D2400/00—Functions or special features of garments
- A41D2400/26—UV light protection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/81—Preparation or application process involves irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
- A61N2005/0652—Arrays of diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
Definitions
- This invention relates to the treatment of damaged and aging skin with light therapy, including both clinical and cosmetic phototreatments.
- antioxidants such as vitamins C and E, glutathione, and enzymes, e.g., superoxide dismutase, are overwhelmed.
- proinflammatory and inflammatory cascades are activated which cause the formation of toxic intermediates and end products, resulting in further, continuous, and ultimately greater damage than that caused by the initial transient reactive species.
- Transcription factors such as NFkB and AP1 are activated, which in turn cause production of proinflammatory mediators.
- cytokines such as tumor necrosis factor ⁇ (TNF ⁇ ) and various interleukins, cause a burst of free radicals.
- Arachadonic acid is released, which is itself toxic, and it is oxidized to biologically active mediators.
- arachadonic acid When arachadonic acid is oxidized via the cyclooxygenase or lipoxygenase pathways, for example, prostaglandins, leukotrines, and hyroxyeicosatetraenoic acid (HETE) are produced, which cause erythma, edema, and additional free radical production accelerating the process.
- HETE hyroxyeicosatetraenoic acid
- the ultimate result of skin aging is that the regularity of tissue structure is lost. Individual cells enlarge, but the total number of cells decreases by at least approximately 30%. Intercellular collagen increases, and the proportion of soluble collagen decreases. Cross-linking between long-chain collagen macromolecules occurs. Elastin loses its discrete structure and elasticity, and has an increased calcium content. The dermis microscars and diminishes.
- Dermatological compositions suggested for the treatment of damaged and aging skin that directly counteract free radical generation metabolic sequelae include tocotrienol preparations (U.S. Pat. No. 5,545,398 to Perricone), precursors of acetylcholine such as dimethylaminoethanol (U.S. Pat. No. 5,554,647 to Perricone), fatty acid esters of ascorbic acid such as ascorbyl palmitate (U.S. Pat. No.
- Damaged skin may also be removed in chemical peels.
- Routine medical procedures typically involve the application of particular chemicals such as trichloroacetic acid, resorcinol or salicylic acid, followed by a short reaction time to allow the chemicals to interact with damaged skin areas. Several days later, the damaged areas peel off. Peels can be uneven, however, and sometimes cause other complications such as prolonged inflammation. Less stringent methods have been developed to remedy some of these problems, such as applying tricholoracetic acid with a surfactant and an emulsifier, and then irradiating to obtain a superficial peel (U.S. Pat. No. 4,874,361 to Obagi).
- the light may be sunlight or artificial light, coherent or noncoherent, pulsed or continuous, of high or low energy, exposed generally or directed to target areas, or any combination of these.
- a variety of irradiation methods may be employed.
- filtered sun or artificial light is used. This can be widely exposed to skin areas, or directed to discrete skin regions, particularly to areas especially susceptible to aging, e.g., the backs of hands and the periorbital and perioral areas of the face.
- light-emitting diodes are applied directly to discrete skin areas as needed as patches or thin sheets such as pliable masks.
- Green light (about 500 to about 590 nm) may be used as adjunct therapy with blue/violet light in some embodiments.
- Compositions containing compounds that enhance light penetration of the stratum corneum such as ⁇ -hydroxy acids (e.g., glycolic acid) may be applied to the skin prior to or during phototreatment.
- This invention is based on the surprising finding that visible short wavelength blue violet light, which is of a wavelength that typically doesn't penetrate skin well, can provide smoothness and radiance to exposed skin surfaces, resulting in a vibrant, healthy skin appearance, and can resolve erythema such as that produced by the UV effects of sunlight.
- skin is irradiated with blue/violet light having a visible wavelength of about 400 nm to about 500 nm for a time and in amounts and energy levels sufficient to provide an observable effect on the skin comprising a decrease in erythema and/or a decrease in the sensory perception of the itching/pain/irritation/warmth described by persons experiencing skin inflammation such as a sunburn, and/or the enhanced appearance of more radiant, vibrant, and healthy skin.
- the irradiation can be continuous or pulsed, coherent or noncoherent, of high or low intensity, or any combination of these.
- the light source may be sunlight or generated by artificial means such as lamps, lasers, or light-emitting diodes (LEDs).
- the blue/violet light may be applied diffusely to exposed skin areas, focused in a pattern corresponding to the configuration of affected areas, targeted to individual especially damaged areas or those particularly susceptible to aging, or delivered to specific skin regions by applying light-emitting diodes in the form of patches or sheets to discrete areas.
- a preferred light source for many embodiments is sunlight.
- Sunlight can be filtered to provide blue violet 400 to 500 nm light using standard optical filters which then provide diffuse blue/green radiation to all of a person's exposed skin surfaces, or, by masking unaffected skin areas, delivered only to selected skin areas that are damaged or inflamed and/or have a tendency to age more than others, such as the eye and mouth regions of the face, the neck, and the backs of the hands.
- sunlight filters that deliver blue/violet light may be incorporated into beach and picnic table umbrellas, visors, hat brims, and the like conventional devices and garments used by people in the sun.
- blue/violet filters may be incorporated into the structures of sunroom roofs and the roofs of tents used for parties, camping, and eating, and into skylights, particularly the skylights of sunrooms, bathrooms, fitness centers, and indoor swimming pools where the advantages of blue/violet light exposure to skin areas outweighs the possible disadvantages of limiting the visible light spectrum delivered by the skylight to the interior.
- This aspect of the invention expressly includes skylights with permanent filters that provide exclusively blue/violet light and those that have removable filters that can be controlled to provide blue/violet light at some times, and other light, including full spectrum visible light, at others, such as conventional skylights having blue/violet light shutters. Once installed, the filtered light effortlessly provides continuous benefits to the skin.
- FIG. 1 For embodiments, Other embodiments employ artificial light such as filtered sunlamp and halogen lamps, flash lamps, filtered fluorescent light, including converted red light (e.g., that disclosed in JP 9054562 to Mitsubishi), light arrays (e.g., U.S. Pat. No. 3,818,914, cited above), and light arranged in a pattern corresponding to affected skin areas (e.g., U.S. Pat. No. 5,944,748 to Mager, et al.). These can be modified to provide special light distribution devices such as that described by Mori, in U.S. Pat. No. 4,838,271.
- indoor lights equipped with permanent or removable filters like sunlight filters, artificial light filters may be of particular benefit in bathrooms, fitness centers, indoor swimming pools, etc., and used on fixtures that provide either continuous or occasional blue/violet light, depending upon the light design.
- LEDs are employed as patches, sheets and the like in alternate embodiments, as these provide an energy source and focused energy delivery to discrete skin areas.
- Preferred among these are thin, flexible, pliable sheets having embedded LEDS which can be applied to specific regions of the body and are easy to use.
- One particularly preferred embodiment is an LED face mask, which may have a neck collar as an auxiliary component.
- An advantage of LED patches or sheets is that they can be easily coupled to optical fibers that simplify light delivery to the treatment region, and the wavelength, pulse length, exposure times, and energy density can be well controlled.
- Lasers are used in alternate embodiments, and are a practical light source for some treatments because their high power output at the appropriate wavelength can minimize exposure times. Like LEDs, laser light can be easily coupled to optical fibers that simplify light delivery to the treatment region, and the wavelength, pulse length, exposure times, and energy density can be well controlled. Lasers include, but are not limited to, tunable dye or solid-state lasers, metal vapor lasers, and diode lasers.
- Light intensity may be varied from high to low, or mixtures thereof.
- low intensity is generally meant light having an intensity of below about 800 mW per centimeter.
- high intensity is generally meant light having an intensity of above about 800 mW/cm 2 .
- a watt is one Joule per second, and optimal irradiation can be gradually and incrementally increased or decreased by 1 to 20 Joules at will or as needed as set out by Tan in U.S. Pat. No. 5,217,455 to achieve optimal results.
- green light is meant visible light having a wavelength of about 500 to about 590 nm. Green light may be used together with blue/violet light in some embodiments, either continuously, intermittently, or alternately. In other embodiments, green light therapy is used after the blue/violet light treatment. In embodiments where green light is used, it is delivered by any of the means described above for the delivery of blue/violet light. It is an advantage of this embodiment that green light can be added to phototreatment of the invention simply by slightly enlarging the visible spectrum of the light shone on the skin. It is another advantage of this embodiment that some positive effects reported for green light therapy may be obtained, such as stimulated cellular repair and removal of fine lines and wrinkles, may enhance results obtained using the phototreatment of the invention.
- compositions containing chemical or physical filters may be administered to skin prior to light therapy in embodiments that employ blue light alone and those that employ blue light and green light.
- composition containing a chemical filter is meant compositions containing one or more compounds that screen out light having a wavelength below about 400 nm and above about 500 nm for the embodiment using blue light alone, and one or more compounds that screen out light having a wavelength below about 400 nm and above about 590 nm for the embodiment employing blue and green light, in a dermatologically acceptable carrier.
- composition containing a physical filter is meant a composition containing fine glass beads, liposomes containing particulate substances that defract light of certain wavelengths, and the like, in a dermatologically acceptable carrier.
- a cream or lotion composition containing at least one chemical filter and/or at least one physical filter are applied to the skin prior to light therapy according to the invention. It is an advantage of this embodiment that any unfiltered light source may be employed.
- One or more active compounds or compositions that enhance light therapy according to the invention are applied in dermatological compositions prior to or during phototreatments of the invention in some embodiments.
- these agents are collectively called “photopenetration enhancers”, and specifically include agents that block visible radiation at wavelengths above the blue/violet region of about 400 to about 500 nm region.
- Photopenetration enhancers include, but are not limited to, ⁇ -hydroxy acids.
- ⁇ -hydroxy acid has reference to and encompasses the general class of organic compounds containing at least one hydroxy group and at least one carboxyl group, and wherein at least one hydroxyl group is located on the ⁇ -carbon atom.
- the compounds are organic acids having at least one carboxylic acid group and at least one hydroxyl group on the ⁇ -carbon atom, and may contain other functional groups including additional hydroxyl and carboxylic acid moieties.
- Preferred ⁇ -hydroxy acids and/or ⁇ -hydroxy acid derivatives are less bulky structurally so that they penetrate the skin well, and thus have a backbone of from one to three carbon atoms such as those set out in U.S. Pat. No. 5,965,618 at column 6 lines 4 to 29. Where employed, glycolic and/or lactic acid or their derivatives are preferred; glycolic acid is especially efficacious.
- photopenetration enhancers topical administration to exposed skin sites prior to irradiation is preferred. Only effective amounts are needed to enhance light therapy, and so generally enhancement is achieved by applying the agents to exposed or affected skin sites. This is typically accomplished in association with a carrier, and particularly one in which the agent is soluble per se or is effectively solubilized (e.g., as an emulsion or microemulsion). Where employed, the carrier is inert in the sense of not bringing about any adverse effect on the skin areas to which it is applied. Suitable carriers include water, alcohols, oils and the like, chosen for their ability to dissolve or disperse the agents and any other ingredients used in the treatment.
- ком ⁇ онент Generally, even low concentrations in a carrier are suitable, depending upon the application regimen and adjunct ingredients employed. Many embodiments contain from about 1% to about 15% by weight, more narrowly from about 5% to about 10% by weight photopenetration enhancers. Where glycolic acid is employed as a photopenetration enhancer, typcal concentrations range from about 1% to about 10% by weight, more narrowly from about 3% to about 7%, by weight glycolic acid.
- compositions containing fat-soluble fatty acid esters of ascorbic acid may be applied to the skin before, during, or after blue/violet light treatments of the invention.
- fat-soluble fatty acid esters of ascorbic acid may be added as an adjunct ingredient to compositions containing photopenetration enhancers.
- the more oxidation-resistant saturated fatty acid esters of ascorbic acid are preferred, including, but not limited to, ascorbyl laurate, ascorbyl myristate, ascorbyl palmitate, ascorbyl stearate, and ascorbyl behenate.
- Ascorbyl palmitate is used in one embodiment.
- esters e.g., ascorbyl stearate
- compositions having predominantly that ester, e.g., predominantly stearate are included.
- the esters may be prepared using hydrogenated oils or fats, or fractions thereof.
- Preferred methods of the invention are easy to use, non-invasive, and safe.
- a particular advantage of some embodiments is simplicity. Exposed skin surfaces may be treated for damage and aging by merely sunbathing, gardening, or picnicking outdoors under a blue/violet light filter in an umbrella, hat brim or visor, or in a room with a blue/violet filtered skylight or artificial light. LED masks provide phototherapeutic facials.
- a further advantage of the invention is that its methods can involve the use of no chemicals applied to hyperallergenic or normal skin.
Abstract
Aging or damaged skin is treated by irradiating affected skin areas with an effective amount of blue and/or violet visible light having a wavelength of about 400 nm to about 500 nm. The light may be sunlight or artificial light, coherent or noncoherent, pulsed or continuous, of high or low energy, exposed generally or directed to target areas, or any combination of these. A variety of irradiation methods may be employed. In one embodiment, filtered sun or artificial light is used. This can be widely exposed to skin areas, or directed to discrete skin regions, particularly to areas especially susceptible to aging, e.g., the backs of hands and the periorbital and perioral areas of the face. In an alternate embodiment, light-emitting diodes are applied directly to discrete skin areas as needed as patches or thin sheets such as pliable masks. Green light (about 500 to about 590 nm) may be used as adjunct therapy with blue/violet light in some embodiments. Compositions containing compounds that enhance light penetration of the stratum corneum such as α-hydroxy acids (e.g., glycolic acid) and/or filter light may be applied to the skin prior to or during phototreatment.
Description
- 1. Field of the Invention.
- This invention relates to the treatment of damaged and aging skin with light therapy, including both clinical and cosmetic phototreatments.
- 2. Description of Related Art.
- Skin inflammation and aging are closely related phenomena. So similar are the processes involved with both, that aging is sometimes described dermatologically as a chronic low grade inflammatory condition. Both inflammation and aging are initiated in part by free radical damage, which takes place mostly within the cell membrane. The cell membrane is most susceptible to attack by free radicals because of its higher oxygen tension in comparison with the cotysol and its dense molecular structure largely comprising lipids and lipoproteins, which are easily oxidized by reactive oxygen species such as singlet oxygen, the superoxide anion, and hydroxyl radicals. These and other free radicals are generated in normal metabolism, as well as through ultraviolet sun exposure, exposure to other forms of ionizing and non-ionizing radiation, environmental factors such as pollution or exposure to chemicals in the home or workplace, and stresses such as infection or extreme exercise. The body's endogenous antioxidant defense systems made up of antioxidants such as vitamins C and E, glutathione, and enzymes, e.g., superoxide dismutase, are overwhelmed.
- In the body's response, proinflammatory and inflammatory cascades are activated which cause the formation of toxic intermediates and end products, resulting in further, continuous, and ultimately greater damage than that caused by the initial transient reactive species. Transcription factors such as NFkB and AP1 are activated, which in turn cause production of proinflammatory mediators. These mediators, called cytokines, such as tumor necrosis factor α (TNFα) and various interleukins, cause a burst of free radicals. Arachadonic acid is released, which is itself toxic, and it is oxidized to biologically active mediators. When arachadonic acid is oxidized via the cyclooxygenase or lipoxygenase pathways, for example, prostaglandins, leukotrines, and hyroxyeicosatetraenoic acid (HETE) are produced, which cause erythma, edema, and additional free radical production accelerating the process. These and other undesirable metabolites permeate and disrupt cell membranes, mitochondrial membranes, and nuclear membranes.
- Incessant membrane damage results in cross-linkage or cleavage of proteins and lipoproteins, and oxidation of membrane lipids and lipoproteins. Cell permeability is diminished, intercellular ionic concentration increases, and cellular capacity to excrete or detoxify waste products is decreased. Waste products such as lipofuscin accumulate. The increase in intercellular ionic potassium concentration causes an increase in colloid density, and m-RNA and protein synthesis are hampered, resulting in decreased cellular repair. Some cells become so dehydrated they cannot function at all. Normal metabolic phosphorylation is gradually uncoupled, resulting in cell necrosis and apoptosis. Activation of transcription factors also elicts gene expression of collagenases which cause additional damage. The ultimate result of skin aging is that the regularity of tissue structure is lost. Individual cells enlarge, but the total number of cells decreases by at least approximately 30%. Intercellular collagen increases, and the proportion of soluble collagen decreases. Cross-linking between long-chain collagen macromolecules occurs. Elastin loses its discrete structure and elasticity, and has an increased calcium content. The dermis microscars and diminishes.
- Sunlight and chemical exposure wreaks far greater destruction on the skin than time itself, and intensifies and augments the aging process. There is substantial evidence that ultraviolet radiation induces the formation of reactive oxygen species that trigger the pathways producing toxic intermediates, contributing to the overall metabolic changes described above (Ibbotson, S. H., et al.,J. Investig. Derm. 112: 933-938, 1999; this paper and others, and the patents cited herein are expressly incorporated in their entireties by reference). Damage to the surface of the skin from sun and chemical exposure is manifested as lines, mottling, discoloration, precancers and cancers.
- Early suggestions for dealing with aging and inflammatory effects on skin were predominantly aimed at lubrications and emollients through use of topical compositions containing soothing agents, e.g., commercial hand lotion products. A bewildering variety of skin creams, lotions and ointments are now available over-the-counter, which typically either act to prevent water loss from the skin or to deliver nutrients into the dermal layers. More recently, attention has been directed to agents which address the underlying processes involved in skin damage, such as the underlying free radical generation processes. In this regard, investigations have been made with respect to the antioxidants vitamin E and vitamin C to quench free radicals on the surface of the skin and to protect lipid membranes intracellularly (Wilson, R.,Drug and Cosmetic Industry, 32-34, 38, and 68, August 1992). Dermatological compositions suggested for the treatment of damaged and aging skin that directly counteract free radical generation metabolic sequelae include tocotrienol preparations (U.S. Pat. No. 5,545,398 to Perricone), precursors of acetylcholine such as dimethylaminoethanol (U.S. Pat. No. 5,554,647 to Perricone), fatty acid esters of ascorbic acid such as ascorbyl palmitate (U.S. Pat. No. 5,574,063 to Perricone), fructose diphosphate (U.S. Pat. No. 6,051,244 to Perricone), catecholamines (U.S. Pat. No. 5,879,690 to Perricone), and polyenylphosphatidylcholine (U.S. Pat. No. 6,191,121 to Perricone).
- Damaged skin may also be removed in chemical peels. Routine medical procedures typically involve the application of particular chemicals such as trichloroacetic acid, resorcinol or salicylic acid, followed by a short reaction time to allow the chemicals to interact with damaged skin areas. Several days later, the damaged areas peel off. Peels can be uneven, however, and sometimes cause other complications such as prolonged inflammation. Less stringent methods have been developed to remedy some of these problems, such as applying tricholoracetic acid with a surfactant and an emulsifier, and then irradiating to obtain a superficial peel (U.S. Pat. No. 4,874,361 to Obagi).
- It would be desirable to have mild alternative therapies for skin damage and aging, particularly for sun damage and wrinkles, that can be used instead of, or in addition to, other methods. It would be especially desirable to have skin treatments that continuously counteract the action of proinflammatory and inflammatory cascades involved in inflammation and aging.
- It is an objective of this invention to provide methods for treating aging or damaged skin by irradiation of affected skin areas with an effective amount of blue and/or violet visible light having a wavelength of about 400 nm to about 500 nm. The light may be sunlight or artificial light, coherent or noncoherent, pulsed or continuous, of high or low energy, exposed generally or directed to target areas, or any combination of these. A variety of irradiation methods may be employed. In one embodiment, filtered sun or artificial light is used. This can be widely exposed to skin areas, or directed to discrete skin regions, particularly to areas especially susceptible to aging, e.g., the backs of hands and the periorbital and perioral areas of the face. In an alternate embodiment, light-emitting diodes are applied directly to discrete skin areas as needed as patches or thin sheets such as pliable masks. Green light (about 500 to about 590 nm) may be used as adjunct therapy with blue/violet light in some embodiments. Compositions containing compounds that enhance light penetration of the stratum corneum such as α-hydroxy acids (e.g., glycolic acid) may be applied to the skin prior to or during phototreatment.
- This invention is based on the surprising finding that visible short wavelength blue violet light, which is of a wavelength that typically doesn't penetrate skin well, can provide smoothness and radiance to exposed skin surfaces, resulting in a vibrant, healthy skin appearance, and can resolve erythema such as that produced by the UV effects of sunlight.
- Light irradiation on skin and other tissues has been suggested for increasing the growth and proliferation of cells, including the acceleration of wound healing and skin grafts (Grossman, N., et al.,J. Invest. Dermatol. 102: 649A, 1994), the control of bacterial infection (WO 98/23329 by Lubart), and the treatment of neoplastic diseases (Colussi, V., et al., Skin Pharm. and Appl. Skin Phys. 11: 336-346, 1998), pigmentations (including tattoos, U.S. Pat. No. 5,217,455 to Tan), psoriasis (U.S. Pat. No. 5,885,557 to Lentini), and acne (Sigurdsson, V., et al., Dermatology 194: 256-260, 1997). These typically involve either UV light (U.S. Pat. No. 3,818,914 to Bender), broad spectrum light having a wavelength between 340 and 3000 nm (ibid.), or long wavelength visible orange/red and infrared light (Lubart, R., et al., J. Photochem. Photobiol B: Biol. 12: 305-310, 1992 and DE 4,440,112 to Wilkens and Wilkens).
- In the practice of the invention, skin is irradiated with blue/violet light having a visible wavelength of about 400 nm to about 500 nm for a time and in amounts and energy levels sufficient to provide an observable effect on the skin comprising a decrease in erythema and/or a decrease in the sensory perception of the itching/pain/irritation/warmth described by persons experiencing skin inflammation such as a sunburn, and/or the enhanced appearance of more radiant, vibrant, and healthy skin. The irradiation can be continuous or pulsed, coherent or noncoherent, of high or low intensity, or any combination of these. The light source may be sunlight or generated by artificial means such as lamps, lasers, or light-emitting diodes (LEDs). The blue/violet light may be applied diffusely to exposed skin areas, focused in a pattern corresponding to the configuration of affected areas, targeted to individual especially damaged areas or those particularly susceptible to aging, or delivered to specific skin regions by applying light-emitting diodes in the form of patches or sheets to discrete areas.
- A preferred light source for many embodiments is sunlight. Sunlight can be filtered to provide blue violet 400 to 500 nm light using standard optical filters which then provide diffuse blue/green radiation to all of a person's exposed skin surfaces, or, by masking unaffected skin areas, delivered only to selected skin areas that are damaged or inflamed and/or have a tendency to age more than others, such as the eye and mouth regions of the face, the neck, and the backs of the hands. In the practice of this embodiment of the invention, sunlight filters that deliver blue/violet light may be incorporated into beach and picnic table umbrellas, visors, hat brims, and the like conventional devices and garments used by people in the sun. By the same token, blue/violet filters may be incorporated into the structures of sunroom roofs and the roofs of tents used for parties, camping, and eating, and into skylights, particularly the skylights of sunrooms, bathrooms, fitness centers, and indoor swimming pools where the advantages of blue/violet light exposure to skin areas outweighs the possible disadvantages of limiting the visible light spectrum delivered by the skylight to the interior. This aspect of the invention expressly includes skylights with permanent filters that provide exclusively blue/violet light and those that have removable filters that can be controlled to provide blue/violet light at some times, and other light, including full spectrum visible light, at others, such as conventional skylights having blue/violet light shutters. Once installed, the filtered light effortlessly provides continuous benefits to the skin.
- Other embodiments employ artificial light such as filtered sunlamp and halogen lamps, flash lamps, filtered fluorescent light, including converted red light (e.g., that disclosed in JP 9054562 to Mitsubishi), light arrays (e.g., U.S. Pat. No. 3,818,914, cited above), and light arranged in a pattern corresponding to affected skin areas (e.g., U.S. Pat. No. 5,944,748 to Mager, et al.). These can be modified to provide special light distribution devices such as that described by Mori, in U.S. Pat. No. 4,838,271. Also encompassed by the invention are indoor lights equipped with permanent or removable filters; like sunlight filters, artificial light filters may be of particular benefit in bathrooms, fitness centers, indoor swimming pools, etc., and used on fixtures that provide either continuous or occasional blue/violet light, depending upon the light design.
- As summarized above, LEDs are employed as patches, sheets and the like in alternate embodiments, as these provide an energy source and focused energy delivery to discrete skin areas. Preferred among these are thin, flexible, pliable sheets having embedded LEDS which can be applied to specific regions of the body and are easy to use. One particularly preferred embodiment is an LED face mask, which may have a neck collar as an auxiliary component. An advantage of LED patches or sheets is that they can be easily coupled to optical fibers that simplify light delivery to the treatment region, and the wavelength, pulse length, exposure times, and energy density can be well controlled.
- Lasers are used in alternate embodiments, and are a practical light source for some treatments because their high power output at the appropriate wavelength can minimize exposure times. Like LEDs, laser light can be easily coupled to optical fibers that simplify light delivery to the treatment region, and the wavelength, pulse length, exposure times, and energy density can be well controlled. Lasers include, but are not limited to, tunable dye or solid-state lasers, metal vapor lasers, and diode lasers.
- Light intensity may be varied from high to low, or mixtures thereof. By “low intensity” is generally meant light having an intensity of below about 800 mW per centimeter. By “high intensity” is generally meant light having an intensity of above about 800 mW/cm2. A watt is one Joule per second, and optimal irradiation can be gradually and incrementally increased or decreased by 1 to 20 Joules at will or as needed as set out by Tan in U.S. Pat. No. 5,217,455 to achieve optimal results.
- Encompassed by the invention are phototreatments that employ green light as adjunct therapy during or after treatment with blue/violet light. By “green” light is meant visible light having a wavelength of about 500 to about 590 nm. Green light may be used together with blue/violet light in some embodiments, either continuously, intermittently, or alternately. In other embodiments, green light therapy is used after the blue/violet light treatment. In embodiments where green light is used, it is delivered by any of the means described above for the delivery of blue/violet light. It is an advantage of this embodiment that green light can be added to phototreatment of the invention simply by slightly enlarging the visible spectrum of the light shone on the skin. It is another advantage of this embodiment that some positive effects reported for green light therapy may be obtained, such as stimulated cellular repair and removal of fine lines and wrinkles, may enhance results obtained using the phototreatment of the invention.
- Dermatological compositions containing chemical or physical filters may be administered to skin prior to light therapy in embodiments that employ blue light alone and those that employ blue light and green light. By a “composition containing a chemical filter” is meant compositions containing one or more compounds that screen out light having a wavelength below about 400 nm and above about 500 nm for the embodiment using blue light alone, and one or more compounds that screen out light having a wavelength below about 400 nm and above about 590 nm for the embodiment employing blue and green light, in a dermatologically acceptable carrier. By a “composition containing a physical filter” is meant a composition containing fine glass beads, liposomes containing particulate substances that defract light of certain wavelengths, and the like, in a dermatologically acceptable carrier. In the typical practice of this embodiment of the invention, a cream or lotion composition containing at least one chemical filter and/or at least one physical filter are applied to the skin prior to light therapy according to the invention. It is an advantage of this embodiment that any unfiltered light source may be employed.
- One or more active compounds or compositions that enhance light therapy according to the invention, including the chemical and optical transparency of the stratum corneum and, most preferably skin absorption of radiation in the blue violet spectral region between about 400 and about 500 nm, are applied in dermatological compositions prior to or during phototreatments of the invention in some embodiments. As used herein, these agents are collectively called “photopenetration enhancers”, and specifically include agents that block visible radiation at wavelengths above the blue/violet region of about 400 to about 500 nm region. Photopenetration enhancers include, but are not limited to, α-hydroxy acids. As used herein, the term “α-hydroxy acid” has reference to and encompasses the general class of organic compounds containing at least one hydroxy group and at least one carboxyl group, and wherein at least one hydroxyl group is located on the α-carbon atom. Typically, the compounds are organic acids having at least one carboxylic acid group and at least one hydroxyl group on the α-carbon atom, and may contain other functional groups including additional hydroxyl and carboxylic acid moieties. Preferred α-hydroxy acids and/or α-hydroxy acid derivatives are less bulky structurally so that they penetrate the skin well, and thus have a backbone of from one to three carbon atoms such as those set out in U.S. Pat. No. 5,965,618 at column 6 lines 4 to 29. Where employed, glycolic and/or lactic acid or their derivatives are preferred; glycolic acid is especially efficacious.
- Where photopenetration enhancers are employed, topical administration to exposed skin sites prior to irradiation is preferred. Only effective amounts are needed to enhance light therapy, and so generally enhancement is achieved by applying the agents to exposed or affected skin sites. This is typically accomplished in association with a carrier, and particularly one in which the agent is soluble per se or is effectively solubilized (e.g., as an emulsion or microemulsion). Where employed, the carrier is inert in the sense of not bringing about any adverse effect on the skin areas to which it is applied. Suitable carriers include water, alcohols, oils and the like, chosen for their ability to dissolve or disperse the agents and any other ingredients used in the treatment. Generally, even low concentrations in a carrier are suitable, depending upon the application regimen and adjunct ingredients employed. Many embodiments contain from about 1% to about 15% by weight, more narrowly from about 5% to about 10% by weight photopenetration enhancers. Where glycolic acid is employed as a photopenetration enhancer, typcal concentrations range from about 1% to about 10% by weight, more narrowly from about 3% to about 7%, by weight glycolic acid.
- Compositions containing fat-soluble fatty acid esters of ascorbic acid (vitamin C) may be applied to the skin before, during, or after blue/violet light treatments of the invention. Alternatively, fat-soluble fatty acid esters of ascorbic acid may be added as an adjunct ingredient to compositions containing photopenetration enhancers. The more oxidation-resistant saturated fatty acid esters of ascorbic acid are preferred, including, but not limited to, ascorbyl laurate, ascorbyl myristate, ascorbyl palmitate, ascorbyl stearate, and ascorbyl behenate. Ascorbyl palmitate is used in one embodiment. As denoted herein, where fatty acid esters are described, e.g., ascorbyl stearate, compositions having predominantly that ester, e.g., predominantly stearate, are included. The esters may be prepared using hydrogenated oils or fats, or fractions thereof.
- Preferred methods of the invention are easy to use, non-invasive, and safe. A particular advantage of some embodiments is simplicity. Exposed skin surfaces may be treated for damage and aging by merely sunbathing, gardening, or picnicking outdoors under a blue/violet light filter in an umbrella, hat brim or visor, or in a room with a blue/violet filtered skylight or artificial light. LED masks provide phototherapeutic facials. A further advantage of the invention is that its methods can involve the use of no chemicals applied to hyperallergenic or normal skin.
- The efficacy of the light treatment methods of the invention was illustrated in observations involving the exposure of the skin of patients having a sun or chemical burn presenting with a low grade, visibly perceptible erythema. The slightly inflamed skin areas were half masked, and exposed to blue/violet filtered summer sunlight or sunlamp light for two hours. Inflammation in skin regions exposed to blue/violet filtered light resolved in approximately half the time as non-treated skin regions in all individuals. Moreover, most patients reported that phototreated skin areas felt less itchy, irritated, painful, and warm. Inviduals with normal skin reported that a two-hour sunbath in blue/violet light made their skin observably smoother, more radiant, vibrant and healthy-looking.
- The above description is for the purpose of teaching the person of ordinary skill in the art how to practice the present invention, and it is not intended to detail all those obvious modifications and variations of it which will become apparent to the skilled worker upon reading the description. It is intended, however, that all such obvious modifications and variations be included within the scope of the present invention, which is defined by the following claims. The claims are intended to cover the claimed components and steps in any sequence which is effective to meet the objectives there intended, unless the context specifically indicates the contrary.
Claims (22)
1. A method for treating aging or damaged skin comprising irradiating the skin with an effective amount of visible light having a wavelength of about 400 nm to about 500 nm.
2. A method according to claim 1 wherein the light has an intensity of below about 800 mW/cm2.
3. A method according to claim 1 wherein the light has an intensity of above about 800 mW/cm2.
4. A method according to claim 1 wherein the light is continuously illuminated on the skin.
5. A method according to claim 1 wherein the light is pulsed.
6. A method according to claim 1 wherein the light is generated from a lamp.
7. A method according to claim 1 wherein the light is filtered sunlight.
8. A method according to claim 1 wherein the light is laser light.
9. A method according to claim 1 wherein the light is emitted from a light-emitting diode.
10. A method according to claim 9 wherein the light-emitting diode is applied directly to the skin as a patch or thin sheet.
11. A method according to claim 1 wherein the skin is also irradiated with visible light having a wavelength of about 500 to about 590 nm.
12. A method according to claim 1 wherein the skin is treated with a dermatological composition containing a chemical filter prior to irradiation.
13. A method according to claim 1 wherein the skin is treated with a dermatological composition containing a physical filter prior to irradiation.
14. A method according to claim 1 wherein the skin is treated with a dermatological composition that enhances the optical transparency of the stratum corneum prior to irradiation.
15. A method according to claim 14 wherein the composition comprises an α-hydroxy acid.
16. A method according to claim 15 wherein the α-hydroxy acid is glycolic acid.
17. A method for treating aging or damaged skin comprising irradiating the skin with an effective amount of filtered blue/violet sunlight having a wavelength of about 400 nm to about 500 nm.
18. A method according to claim 17 wherein the skin is irradiated through an umbrella, visor, or hat brim comprising a blue/violet filter.
19. A method according to claim 17 wherein the skin is irradiated through a skylight having a blue/green filter.
20. A method for treating aging or damaged skin comprising applying directly to affected skin areas light-emitting diodes that irradiate the skin with visible light having a wavelength of about 400 nm to about 500 nm.
21. A method according to claim 20 wherein the light-emitting diodes are applied to the skin as skin patches.
22. A method according to claim 20 wherein the light-emitting diodes are applied to the skin in a face mask.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/901,847 US20030009158A1 (en) | 2001-07-09 | 2001-07-09 | Skin treatments using blue and violet light |
PCT/US2002/021599 WO2003005883A2 (en) | 2001-07-09 | 2002-07-08 | Skin treatments using blue and violet light |
US10/609,743 US7066941B2 (en) | 2001-07-09 | 2003-06-30 | Apparatus for skin treatment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/901,847 US20030009158A1 (en) | 2001-07-09 | 2001-07-09 | Skin treatments using blue and violet light |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/609,743 Continuation-In-Part US7066941B2 (en) | 2001-07-09 | 2003-06-30 | Apparatus for skin treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030009158A1 true US20030009158A1 (en) | 2003-01-09 |
Family
ID=25414913
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/901,847 Abandoned US20030009158A1 (en) | 2001-07-09 | 2001-07-09 | Skin treatments using blue and violet light |
US10/609,743 Expired - Lifetime US7066941B2 (en) | 2001-07-09 | 2003-06-30 | Apparatus for skin treatment |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/609,743 Expired - Lifetime US7066941B2 (en) | 2001-07-09 | 2003-06-30 | Apparatus for skin treatment |
Country Status (2)
Country | Link |
---|---|
US (2) | US20030009158A1 (en) |
WO (1) | WO2003005883A2 (en) |
Cited By (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2390021A (en) * | 2002-05-17 | 2003-12-31 | Ian Charlesworth | Hand-held led apparatus for treating acne |
US20040167502A1 (en) * | 2003-02-25 | 2004-08-26 | Weckwerth Mark V. | Optical sensor and method for identifying the presence of skin |
US20040167499A1 (en) * | 2003-02-25 | 2004-08-26 | Grove Robert E. | Eye-safe dermatologic treatment apparatus and method |
US20040167500A1 (en) * | 2003-02-25 | 2004-08-26 | Weckwerth Mark V. | Self-contained, diode-laser-based dermatologic treatment apparatus and method |
US20040176823A1 (en) * | 2003-02-25 | 2004-09-09 | Island Tobin C. | Acne treatment device and method |
US20040176754A1 (en) * | 2003-03-06 | 2004-09-09 | Island Tobin C. | Method and device for sensing skin contact |
US20040199227A1 (en) * | 2001-11-29 | 2004-10-07 | Altshuler Gregory B. | Biostimulation of the oral cavity |
US20040230259A1 (en) * | 2003-02-26 | 2004-11-18 | Di Matteo Thierry Fabio | Apparatus and method for treatment of acne |
US20050021012A1 (en) * | 2001-12-12 | 2005-01-27 | Bernstein Eric F | Laser treatment for reducing wrinkles |
US20050055070A1 (en) * | 2003-03-07 | 2005-03-10 | Gareth Jones | Method and device for treatment of skin conditions |
US20060004347A1 (en) * | 2000-12-28 | 2006-01-05 | Palomar Medical Technologies, Inc. | Methods and products for producing lattices of EMR-treated islets in tissues, and uses therefor |
US20060030908A1 (en) * | 2004-08-09 | 2006-02-09 | Lumiport, Llc | Skin treatment phototherapy device |
WO2006020197A1 (en) | 2004-07-16 | 2006-02-23 | Johnson & Johnson Consumer Companies, Inc. | Treatment of skin with light and a benefit agent to mitigate acne |
US20060216251A1 (en) * | 2005-03-24 | 2006-09-28 | Tracie Martyn International, Llc | Topical formulations and methods of use |
US20060229689A1 (en) * | 2005-04-08 | 2006-10-12 | Led Technologies, Llc | LED therapy device |
US20070016173A1 (en) * | 2005-07-14 | 2007-01-18 | Michael Kreindel | Protective material, clothing item and method of protection |
US20070027440A1 (en) * | 2001-03-02 | 2007-02-01 | Palomar Medical Technologies, Inc. | Apparatus and method for photocosmetic and photodermatological treatment |
US20070038271A1 (en) * | 2004-07-16 | 2007-02-15 | Cole Curtis A | Treatment of skin with light and a benefit agent |
US20070049910A1 (en) * | 2005-08-08 | 2007-03-01 | Palomar Medical Technologies, Inc. | Eye-safe photocosmetic device |
US20070060819A1 (en) * | 2005-09-15 | 2007-03-15 | Palomar Medical Technologies, Inc. | Skin optical characterization device |
US20070213792A1 (en) * | 2002-10-07 | 2007-09-13 | Palomar Medical Technologies, Inc. | Treatment Of Tissue Volume With Radiant Energy |
US20070271714A1 (en) * | 2006-03-17 | 2007-11-29 | Light Dimensions, Inc. | Light-based enhancing apparatuses and methods of use |
US20080027518A1 (en) * | 2003-02-25 | 2008-01-31 | Spectragenics, Inc. | Self-contained, eye-safe hair-regrowth-inhibition apparatus and method |
US20080033516A1 (en) * | 2002-10-07 | 2008-02-07 | Palomar Medical Technologies, Inc. | Methods and apparatus for performing photobiostimulation |
US20080038306A1 (en) * | 2006-03-13 | 2008-02-14 | David Nathaniel E | Fluidic Tissue Augmentation Compositions and Methods |
US20080091250A1 (en) * | 2002-09-26 | 2008-04-17 | Lumiport, Llc | Light therapy desk lamp |
US20080103560A1 (en) * | 2006-10-26 | 2008-05-01 | Lumiport, Llc | Ultraviolet indicator light therapy device |
US20080103565A1 (en) * | 2002-06-19 | 2008-05-01 | Palomar Medical Technologies, Inc. | Method and apparatus for treatment of cutaneous and subcutaneous conditions |
US20080103563A1 (en) * | 2006-10-26 | 2008-05-01 | Lumiport, Llc | Light therapy personal care device |
US20080119913A1 (en) * | 2006-10-26 | 2008-05-22 | Lumiport, Llc | Light therapy personal care device |
US20080132886A1 (en) * | 2004-04-09 | 2008-06-05 | Palomar Medical Technologies, Inc. | Use of fractional emr technology on incisions and internal tissues |
US20080154157A1 (en) * | 2006-12-13 | 2008-06-26 | Palomar Medical Technologies, Inc. | Cosmetic and biomedical applications of ultrasonic energy and methods of generation thereof |
US20080275533A1 (en) * | 2007-05-04 | 2008-11-06 | Powell Steven D | Display apparatus for providing information and therapeutic light |
US20090012511A1 (en) * | 2007-06-08 | 2009-01-08 | Cynosure, Inc. | Surgical waveguide |
US20090043294A1 (en) * | 2003-02-25 | 2009-02-12 | Spectragenics, Inc. | Capacitive Sensing Method and Device for Detecting Skin |
US20090149922A1 (en) * | 2007-12-06 | 2009-06-11 | Susan Lemons White | Treatment of ear infection using blue/violet light |
US20090149924A1 (en) * | 2007-12-06 | 2009-06-11 | Susan Lemons White | Treatment of ear infection using hands-free blue/violet light device |
US20090204109A1 (en) * | 2003-02-25 | 2009-08-13 | Tria Beauty, Inc. | Eye-Safe Dermatologic Treatment Apparatus and Method |
US20090270848A1 (en) * | 2008-04-25 | 2009-10-29 | Tria Beauty, Inc. | Optical Sensor and Method for Identifying the Presence of Skin and the Pigmentation of Skin |
US20090292277A1 (en) * | 2006-08-02 | 2009-11-26 | Cynosure, Inc. | Picosecond laser apparatus and methods for its operation and use |
US20100069898A1 (en) * | 2003-02-25 | 2010-03-18 | Tria Beauty, Inc. | Acne Treatment Method, System and Device |
US7763016B2 (en) | 1997-05-15 | 2010-07-27 | Palomar Medical Technologies, Inc. | Light energy delivery head |
US20100204686A1 (en) * | 2002-12-20 | 2010-08-12 | Palomar Medical Technologies, Inc. | Light treatments for acne and other disorders of follicles |
US7935107B2 (en) | 1997-05-15 | 2011-05-03 | Palomar Medical Technologies, Inc. | Heads for dermatology treatment |
US7942916B2 (en) | 2002-05-23 | 2011-05-17 | Palomar Medical Technologies, Inc. | Phototreatment device for use with coolants and topical substances |
US7981111B2 (en) | 2003-02-25 | 2011-07-19 | Tria Beauty, Inc. | Method and apparatus for the treatment of benign pigmented lesions |
US8182473B2 (en) | 1999-01-08 | 2012-05-22 | Palomar Medical Technologies | Cooling system for a photocosmetic device |
US20120310307A1 (en) * | 2011-06-01 | 2012-12-06 | Bo Zhou | Treatment of fungal infection by light irradiation |
US8328794B2 (en) | 1996-12-02 | 2012-12-11 | Palomar Medical Technologies, Inc. | System for electromagnetic radiation dermatology and head for use therewith |
WO2013060407A1 (en) * | 2011-10-29 | 2013-05-02 | Merck Patent Gmbh | Skin lightener in phototherapy |
US20140128780A1 (en) * | 2011-04-01 | 2014-05-08 | Syneron Beauty Ltd | Treatment Device |
US8777935B2 (en) | 2004-02-25 | 2014-07-15 | Tria Beauty, Inc. | Optical sensor and method for identifying the presence of skin |
US20160250497A1 (en) * | 2003-08-26 | 2016-09-01 | Harvey Jay | Skin Treatment System and Method |
US20170027210A1 (en) * | 2014-04-14 | 2017-02-02 | Biothera, Inc. | Yeast cell wall enriched in mannan oligosaccharide protein |
US9780518B2 (en) | 2012-04-18 | 2017-10-03 | Cynosure, Inc. | Picosecond laser apparatus and methods for treating target tissues with same |
US9919168B2 (en) | 2009-07-23 | 2018-03-20 | Palomar Medical Technologies, Inc. | Method for improvement of cellulite appearance |
CN108392629A (en) * | 2017-02-08 | 2018-08-14 | 强生消费者公司 | The composition and method of skin disorder are treated with illumination and polybasic carboxylic acid |
US10245107B2 (en) | 2013-03-15 | 2019-04-02 | Cynosure, Inc. | Picosecond optical radiation systems and methods of use |
US10309614B1 (en) | 2017-12-05 | 2019-06-04 | Vital Vivo, Inc. | Light directing element |
US10357582B1 (en) | 2015-07-30 | 2019-07-23 | Vital Vio, Inc. | Disinfecting lighting device |
US10413626B1 (en) | 2018-03-29 | 2019-09-17 | Vital Vio, Inc. | Multiple light emitter for inactivating microorganisms |
US10434324B2 (en) | 2005-04-22 | 2019-10-08 | Cynosure, Llc | Methods and systems for laser treatment using non-uniform output beam |
US10617774B2 (en) | 2017-12-01 | 2020-04-14 | Vital Vio, Inc. | Cover with disinfecting illuminated surface |
US10753575B2 (en) | 2015-07-30 | 2020-08-25 | Vital Vio, Inc. | Single diode disinfection |
US10918747B2 (en) | 2015-07-30 | 2021-02-16 | Vital Vio, Inc. | Disinfecting lighting device |
US10939517B2 (en) | 2019-05-15 | 2021-03-02 | SABER Corporation | Feedback control of light emitting devices using fluorescent components and light sensors |
US11285335B2 (en) | 2018-10-08 | 2022-03-29 | Biohacked, Inc. | Photo-therapeutic method and apparatus |
US11369704B2 (en) | 2019-08-15 | 2022-06-28 | Vyv, Inc. | Devices configured to disinfect interiors |
US11418000B2 (en) | 2018-02-26 | 2022-08-16 | Cynosure, Llc | Q-switched cavity dumped sub-nanosecond laser |
US11541135B2 (en) | 2019-06-28 | 2023-01-03 | Vyv, Inc. | Multiple band visible light disinfection |
US11639897B2 (en) | 2019-03-29 | 2023-05-02 | Vyv, Inc. | Contamination load sensing device |
US11878084B2 (en) | 2019-09-20 | 2024-01-23 | Vyv, Inc. | Disinfecting light emitting subcomponent |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060212025A1 (en) | 1998-11-30 | 2006-09-21 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US9192780B2 (en) | 1998-11-30 | 2015-11-24 | L'oreal | Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders |
US6887260B1 (en) | 1998-11-30 | 2005-05-03 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US7267673B2 (en) * | 2002-12-12 | 2007-09-11 | Pacific Biosciences Laboratories, Inc. | System for treatment of acne skin condition using a narrow band light source |
EP1617777A4 (en) | 2003-04-10 | 2010-11-03 | Gentlewaves Llc | Photomodulation methods and devices for regulating cell proliferation and gene expression |
US6989023B2 (en) * | 2003-07-08 | 2006-01-24 | Oralum, Llc | Hygienic treatments of body structures |
US20060183072A1 (en) * | 2003-04-25 | 2006-08-17 | Michael Black | Device for application of multiple hygienic effects |
US7144247B2 (en) * | 2003-04-25 | 2006-12-05 | Oralum, Llc | Hygienic treatments of structures in body cavities |
WO2005011606A2 (en) | 2003-07-31 | 2005-02-10 | Light Bioscience, Llc | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
US20060235371A1 (en) * | 2005-04-07 | 2006-10-19 | Shingo Wakamatsu | Microscopic-spots irradiating device applying a vacuum thereto |
DK2352488T3 (en) | 2008-11-07 | 2017-03-27 | Klox Tech Inc | OXIDATIVE PHOTO-ACTIVATED SKIN REFRESHING COMPOSITION INCLUDING HYALURONIC ACID, GLUCOSAMINE, OR ALLANTOIN |
ITPI20090017A1 (en) * | 2009-02-27 | 2010-08-28 | Federico Biffignandi | DEVICE FOR CHROMOTHERAPY CONSTITUTED BY ILLUMINATED LOCAL BY CONVEYED SUNLIGHT THROUGH TUBULAR SKYLIGHT AND FILTERED BY CHROMATIC FILTERS IN GLASS, CRYSTAL OR SYNTHETIC MATERIAL OF THE SELECTED COLOR |
WO2011001342A1 (en) * | 2009-06-30 | 2011-01-06 | Koninklijke Philips Electronics N.V. | Body illumination system for controlling the biological clock of a mammal by radiation exposure of the skin |
HUE035716T2 (en) | 2009-07-17 | 2018-05-28 | Klox Tech Inc | Antibacterial oral composition |
KR101180607B1 (en) | 2010-10-26 | 2012-09-06 | 전북대학교산학협력단 | A combined treatment device using phototherapy, hyperthermia and electromagnetic stimulus |
KR102407182B1 (en) | 2011-05-31 | 2022-06-10 | 클라렌슈 피티와이 리미티드 | Light therapy apparatuses |
DK2800605T4 (en) * | 2012-01-03 | 2023-02-06 | Benesol Inc | PHOTOTHERAPEUTIC APPARATUS FOR FOCUSED UVB RADIATION AND VITAMIN D SYNTHESIS AND ASSOCIATED SYSTEMS |
US11116841B2 (en) | 2012-04-20 | 2021-09-14 | Klox Technologies Inc. | Biophotonic compositions, kits and methods |
US20130281913A1 (en) | 2012-04-20 | 2013-10-24 | Klox Technologies Inc. | Biophotonic compositions and methods for providing biophotonic treatment |
US20150360047A1 (en) * | 2012-09-14 | 2015-12-17 | Klox Technologies Inc. | Cosmetic Biophotonic Compositions |
US10589120B1 (en) | 2012-12-31 | 2020-03-17 | Gary John Bellinger | High-intensity laser therapy method and apparatus |
CA2902360A1 (en) * | 2013-03-01 | 2014-09-04 | Klox Technologies Inc. | Phototherapeutic device, method and use |
CN105339042A (en) * | 2013-03-01 | 2016-02-17 | 克洛克斯科技公司 | Phototherapeutic device, method and use |
US20140276354A1 (en) | 2013-03-14 | 2014-09-18 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
MX366292B (en) * | 2013-07-03 | 2019-07-04 | Klox Tech Inc | Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds. |
US20160016001A1 (en) * | 2014-02-28 | 2016-01-21 | Klox Technologies Inc. | Phototherapeutic device, method and use |
CN106413766A (en) | 2014-04-01 | 2017-02-15 | 克洛克斯科技公司 | Tissue filler compositions and methods of use |
USD762870S1 (en) | 2014-07-30 | 2016-08-02 | Vijay Singh | LED light therapy tape |
US11421349B2 (en) | 2014-10-31 | 2022-08-23 | Klox Technologies Inc. | Photoactivatable fibers and fabric media |
CN108289892B (en) | 2015-06-29 | 2021-11-23 | 维瑞斯特姆股份有限公司 | Therapeutic compositions, combinations and methods of use |
US10155122B1 (en) | 2017-05-30 | 2018-12-18 | William Woodburn | Device for photo-therapy of grover's disease and use thereof |
US11273320B2 (en) | 2017-05-30 | 2022-03-15 | Tcellerate Llc | Device for photo-therapy of Grover's disease and use thereof |
CN110769895A (en) * | 2017-06-20 | 2020-02-07 | 公立大学法人名古屋市立大学 | Photodynamic therapeutic light irradiation device |
US11241374B2 (en) | 2018-06-28 | 2022-02-08 | Johnson & Johnson Consumer Inc. | Compositions and methods for treating skin conditions using light and glucosamine hydrochloride |
US20200405603A1 (en) | 2019-06-25 | 2020-12-31 | Johnson & Johnson Consumer Inc. | Compositions and methods for treating skin conditions using infrared light and resorcinols |
CA3184497A1 (en) | 2021-12-30 | 2023-06-30 | Tcellerate Llc | Device for photo-therapy and use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5503637A (en) * | 1987-06-26 | 1996-04-02 | Light Sciences, Inc. | Apparatus for producing and delivering high-intensity light to a subject |
US5620478A (en) * | 1992-10-20 | 1997-04-15 | Esc Medical Systems Ltd. | Method and apparatus for therapeutic electromagnetic treatment |
US5586981A (en) * | 1994-08-25 | 1996-12-24 | Xin-Hua Hu | Treatment of cutaneous vascular and pigmented lesions |
US5913883A (en) * | 1996-08-06 | 1999-06-22 | Alexander; Dane | Therapeutic facial mask |
US6063108A (en) * | 1997-01-06 | 2000-05-16 | Salansky; Norman | Method and apparatus for localized low energy photon therapy (LEPT) |
US6312450B1 (en) * | 1997-05-20 | 2001-11-06 | Natural Vision Center, Inc. | System and method for improving the appearance of skin |
-
2001
- 2001-07-09 US US09/901,847 patent/US20030009158A1/en not_active Abandoned
-
2002
- 2002-07-08 WO PCT/US2002/021599 patent/WO2003005883A2/en not_active Application Discontinuation
-
2003
- 2003-06-30 US US10/609,743 patent/US7066941B2/en not_active Expired - Lifetime
Cited By (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8328794B2 (en) | 1996-12-02 | 2012-12-11 | Palomar Medical Technologies, Inc. | System for electromagnetic radiation dermatology and head for use therewith |
US7763016B2 (en) | 1997-05-15 | 2010-07-27 | Palomar Medical Technologies, Inc. | Light energy delivery head |
US8328796B2 (en) | 1997-05-15 | 2012-12-11 | Palomar Medical Technologies, Inc. | Light energy delivery head |
US8109924B2 (en) | 1997-05-15 | 2012-02-07 | Palomar Medical Technologies, Inc. | Heads for dermatology treatment |
US8002768B1 (en) | 1997-05-15 | 2011-08-23 | Palomar Medical Technologies, Inc. | Light energy delivery head |
US7935107B2 (en) | 1997-05-15 | 2011-05-03 | Palomar Medical Technologies, Inc. | Heads for dermatology treatment |
US8182473B2 (en) | 1999-01-08 | 2012-05-22 | Palomar Medical Technologies | Cooling system for a photocosmetic device |
US20060004347A1 (en) * | 2000-12-28 | 2006-01-05 | Palomar Medical Technologies, Inc. | Methods and products for producing lattices of EMR-treated islets in tissues, and uses therefor |
US20070027440A1 (en) * | 2001-03-02 | 2007-02-01 | Palomar Medical Technologies, Inc. | Apparatus and method for photocosmetic and photodermatological treatment |
US20040199227A1 (en) * | 2001-11-29 | 2004-10-07 | Altshuler Gregory B. | Biostimulation of the oral cavity |
US20050021012A1 (en) * | 2001-12-12 | 2005-01-27 | Bernstein Eric F | Laser treatment for reducing wrinkles |
GB2390021A (en) * | 2002-05-17 | 2003-12-31 | Ian Charlesworth | Hand-held led apparatus for treating acne |
US7942915B2 (en) | 2002-05-23 | 2011-05-17 | Palomar Medical Technologies, Inc. | Phototreatment device for use with coolants |
US7942916B2 (en) | 2002-05-23 | 2011-05-17 | Palomar Medical Technologies, Inc. | Phototreatment device for use with coolants and topical substances |
US10556123B2 (en) | 2002-06-19 | 2020-02-11 | Palomar Medical Technologies, Llc | Method and apparatus for treatment of cutaneous and subcutaneous conditions |
US8915948B2 (en) | 2002-06-19 | 2014-12-23 | Palomar Medical Technologies, Llc | Method and apparatus for photothermal treatment of tissue at depth |
US20080103565A1 (en) * | 2002-06-19 | 2008-05-01 | Palomar Medical Technologies, Inc. | Method and apparatus for treatment of cutaneous and subcutaneous conditions |
US10500413B2 (en) | 2002-06-19 | 2019-12-10 | Palomar Medical Technologies, Llc | Method and apparatus for treatment of cutaneous and subcutaneous conditions |
US20090024193A1 (en) * | 2002-06-19 | 2009-01-22 | Palomar Medical Technologies, Inc. | Method And Apparatus For Photothermal Treatment Of Tissue At Depth |
US20080091250A1 (en) * | 2002-09-26 | 2008-04-17 | Lumiport, Llc | Light therapy desk lamp |
US20070213792A1 (en) * | 2002-10-07 | 2007-09-13 | Palomar Medical Technologies, Inc. | Treatment Of Tissue Volume With Radiant Energy |
US20080033516A1 (en) * | 2002-10-07 | 2008-02-07 | Palomar Medical Technologies, Inc. | Methods and apparatus for performing photobiostimulation |
US20100204686A1 (en) * | 2002-12-20 | 2010-08-12 | Palomar Medical Technologies, Inc. | Light treatments for acne and other disorders of follicles |
US20080027518A1 (en) * | 2003-02-25 | 2008-01-31 | Spectragenics, Inc. | Self-contained, eye-safe hair-regrowth-inhibition apparatus and method |
US10342618B2 (en) | 2003-02-25 | 2019-07-09 | Channel Investments, Llc | Self-contained, eye-safe hair-regrowth-inhibition apparatus and method |
US20040167499A1 (en) * | 2003-02-25 | 2004-08-26 | Grove Robert E. | Eye-safe dermatologic treatment apparatus and method |
US20090043294A1 (en) * | 2003-02-25 | 2009-02-12 | Spectragenics, Inc. | Capacitive Sensing Method and Device for Detecting Skin |
US20040167502A1 (en) * | 2003-02-25 | 2004-08-26 | Weckwerth Mark V. | Optical sensor and method for identifying the presence of skin |
US20040176823A1 (en) * | 2003-02-25 | 2004-09-09 | Island Tobin C. | Acne treatment device and method |
US20070032847A1 (en) * | 2003-02-25 | 2007-02-08 | Spectragenics, Inc. | Self-contained, diode-laser-based dermatologic treatment apparatus |
US8709003B2 (en) | 2003-02-25 | 2014-04-29 | Tria Beauty, Inc. | Capacitive sensing method and device for detecting skin |
US10342617B2 (en) | 2003-02-25 | 2019-07-09 | Channel Investments, Llc | Phototherapy device thermal control apparatus and method |
US7981111B2 (en) | 2003-02-25 | 2011-07-19 | Tria Beauty, Inc. | Method and apparatus for the treatment of benign pigmented lesions |
US20040167500A1 (en) * | 2003-02-25 | 2004-08-26 | Weckwerth Mark V. | Self-contained, diode-laser-based dermatologic treatment apparatus and method |
US20100069898A1 (en) * | 2003-02-25 | 2010-03-18 | Tria Beauty, Inc. | Acne Treatment Method, System and Device |
US20090204109A1 (en) * | 2003-02-25 | 2009-08-13 | Tria Beauty, Inc. | Eye-Safe Dermatologic Treatment Apparatus and Method |
US8551104B2 (en) | 2003-02-25 | 2013-10-08 | Tria Beauty, Inc. | Self-contained, diode-laser-based dermatologic treatment apparatus |
US20040230259A1 (en) * | 2003-02-26 | 2004-11-18 | Di Matteo Thierry Fabio | Apparatus and method for treatment of acne |
US20040176754A1 (en) * | 2003-03-06 | 2004-09-09 | Island Tobin C. | Method and device for sensing skin contact |
US20050055070A1 (en) * | 2003-03-07 | 2005-03-10 | Gareth Jones | Method and device for treatment of skin conditions |
US20160250497A1 (en) * | 2003-08-26 | 2016-09-01 | Harvey Jay | Skin Treatment System and Method |
US8777935B2 (en) | 2004-02-25 | 2014-07-15 | Tria Beauty, Inc. | Optical sensor and method for identifying the presence of skin |
US20080132886A1 (en) * | 2004-04-09 | 2008-06-05 | Palomar Medical Technologies, Inc. | Use of fractional emr technology on incisions and internal tissues |
US20070038271A1 (en) * | 2004-07-16 | 2007-02-15 | Cole Curtis A | Treatment of skin with light and a benefit agent |
WO2006020197A1 (en) | 2004-07-16 | 2006-02-23 | Johnson & Johnson Consumer Companies, Inc. | Treatment of skin with light and a benefit agent to mitigate acne |
WO2006020602A1 (en) * | 2004-08-09 | 2006-02-23 | Lumiport, Llc | Skin treatment phototherapy device |
US20080065056A1 (en) * | 2004-08-09 | 2008-03-13 | Lumiport, Llc | Skin treatment phototherapy method |
US20090227996A1 (en) * | 2004-08-09 | 2009-09-10 | Enormx, Llc | Skin treatment phototherapy method |
US20090254156A1 (en) * | 2004-08-09 | 2009-10-08 | Lumiport, Llc | Skin treatment phototherapy device |
US20060030908A1 (en) * | 2004-08-09 | 2006-02-09 | Lumiport, Llc | Skin treatment phototherapy device |
US7776915B2 (en) | 2005-03-24 | 2010-08-17 | Tracie Martyn International, Llc | Topical formulations and methods of use |
US20060216251A1 (en) * | 2005-03-24 | 2006-09-28 | Tracie Martyn International, Llc | Topical formulations and methods of use |
US20060229689A1 (en) * | 2005-04-08 | 2006-10-12 | Led Technologies, Llc | LED therapy device |
US10434324B2 (en) | 2005-04-22 | 2019-10-08 | Cynosure, Llc | Methods and systems for laser treatment using non-uniform output beam |
WO2007006102A1 (en) * | 2005-07-14 | 2007-01-18 | Sunsoul Inc. | Protective material, clothing item and method of protection |
US20080179573A1 (en) * | 2005-07-14 | 2008-07-31 | Michael Kreindel | Protective material, clothing item and method of protection |
US8084377B2 (en) | 2005-07-14 | 2011-12-27 | Sun-Soul Inc. | Protective material, clothing item and method of protection |
US20070016173A1 (en) * | 2005-07-14 | 2007-01-18 | Michael Kreindel | Protective material, clothing item and method of protection |
US20070049910A1 (en) * | 2005-08-08 | 2007-03-01 | Palomar Medical Technologies, Inc. | Eye-safe photocosmetic device |
US8346347B2 (en) | 2005-09-15 | 2013-01-01 | Palomar Medical Technologies, Inc. | Skin optical characterization device |
US20070060819A1 (en) * | 2005-09-15 | 2007-03-15 | Palomar Medical Technologies, Inc. | Skin optical characterization device |
US20110087152A1 (en) * | 2006-03-13 | 2011-04-14 | David Nathaniel E | Fluidic tissue augmentation compositions and methods |
US20080038306A1 (en) * | 2006-03-13 | 2008-02-14 | David Nathaniel E | Fluidic Tissue Augmentation Compositions and Methods |
US20070271714A1 (en) * | 2006-03-17 | 2007-11-29 | Light Dimensions, Inc. | Light-based enhancing apparatuses and methods of use |
US11712299B2 (en) | 2006-08-02 | 2023-08-01 | Cynosure, LLC. | Picosecond laser apparatus and methods for its operation and use |
US10849687B2 (en) | 2006-08-02 | 2020-12-01 | Cynosure, Llc | Picosecond laser apparatus and methods for its operation and use |
US20090292277A1 (en) * | 2006-08-02 | 2009-11-26 | Cynosure, Inc. | Picosecond laser apparatus and methods for its operation and use |
US10966785B2 (en) | 2006-08-02 | 2021-04-06 | Cynosure, Llc | Picosecond laser apparatus and methods for its operation and use |
US9028536B2 (en) | 2006-08-02 | 2015-05-12 | Cynosure, Inc. | Picosecond laser apparatus and methods for its operation and use |
US20080103560A1 (en) * | 2006-10-26 | 2008-05-01 | Lumiport, Llc | Ultraviolet indicator light therapy device |
US20080103563A1 (en) * | 2006-10-26 | 2008-05-01 | Lumiport, Llc | Light therapy personal care device |
US20080119913A1 (en) * | 2006-10-26 | 2008-05-22 | Lumiport, Llc | Light therapy personal care device |
US20080154157A1 (en) * | 2006-12-13 | 2008-06-26 | Palomar Medical Technologies, Inc. | Cosmetic and biomedical applications of ultrasonic energy and methods of generation thereof |
US20080275533A1 (en) * | 2007-05-04 | 2008-11-06 | Powell Steven D | Display apparatus for providing information and therapeutic light |
US20090012511A1 (en) * | 2007-06-08 | 2009-01-08 | Cynosure, Inc. | Surgical waveguide |
US20090149922A1 (en) * | 2007-12-06 | 2009-06-11 | Susan Lemons White | Treatment of ear infection using blue/violet light |
US8021405B2 (en) | 2007-12-06 | 2011-09-20 | Susan Lemons White | Treatment of ear infection using blue/violet light |
US20090149924A1 (en) * | 2007-12-06 | 2009-06-11 | Susan Lemons White | Treatment of ear infection using hands-free blue/violet light device |
US9687671B2 (en) | 2008-04-25 | 2017-06-27 | Channel Investments, Llc | Optical sensor and method for identifying the presence of skin and the pigmentation of skin |
US20090270848A1 (en) * | 2008-04-25 | 2009-10-29 | Tria Beauty, Inc. | Optical Sensor and Method for Identifying the Presence of Skin and the Pigmentation of Skin |
US9919168B2 (en) | 2009-07-23 | 2018-03-20 | Palomar Medical Technologies, Inc. | Method for improvement of cellulite appearance |
US20140128780A1 (en) * | 2011-04-01 | 2014-05-08 | Syneron Beauty Ltd | Treatment Device |
US20120310307A1 (en) * | 2011-06-01 | 2012-12-06 | Bo Zhou | Treatment of fungal infection by light irradiation |
US20140323950A1 (en) * | 2011-10-29 | 2014-10-30 | Merck Patent Gmbh | Skin lightener in phototherapy |
WO2013060407A1 (en) * | 2011-10-29 | 2013-05-02 | Merck Patent Gmbh | Skin lightener in phototherapy |
JP2014532672A (en) * | 2011-10-29 | 2014-12-08 | メルク パテント ゲーエムベーハー | Whitening agent used for phototherapy |
US11664637B2 (en) | 2012-04-18 | 2023-05-30 | Cynosure, Llc | Picosecond laser apparatus and methods for treating target tissues with same |
US11095087B2 (en) | 2012-04-18 | 2021-08-17 | Cynosure, Llc | Picosecond laser apparatus and methods for treating target tissues with same |
US10305244B2 (en) | 2012-04-18 | 2019-05-28 | Cynosure, Llc | Picosecond laser apparatus and methods for treating target tissues with same |
US9780518B2 (en) | 2012-04-18 | 2017-10-03 | Cynosure, Inc. | Picosecond laser apparatus and methods for treating target tissues with same |
US10581217B2 (en) | 2012-04-18 | 2020-03-03 | Cynosure, Llc | Picosecond laser apparatus and methods for treating target tissues with same |
US10765478B2 (en) | 2013-03-15 | 2020-09-08 | Cynosurce, Llc | Picosecond optical radiation systems and methods of use |
US10285757B2 (en) | 2013-03-15 | 2019-05-14 | Cynosure, Llc | Picosecond optical radiation systems and methods of use |
US11446086B2 (en) | 2013-03-15 | 2022-09-20 | Cynosure, Llc | Picosecond optical radiation systems and methods of use |
US10245107B2 (en) | 2013-03-15 | 2019-04-02 | Cynosure, Inc. | Picosecond optical radiation systems and methods of use |
US20170027210A1 (en) * | 2014-04-14 | 2017-02-02 | Biothera, Inc. | Yeast cell wall enriched in mannan oligosaccharide protein |
US10753575B2 (en) | 2015-07-30 | 2020-08-25 | Vital Vio, Inc. | Single diode disinfection |
US10357582B1 (en) | 2015-07-30 | 2019-07-23 | Vital Vio, Inc. | Disinfecting lighting device |
US10918747B2 (en) | 2015-07-30 | 2021-02-16 | Vital Vio, Inc. | Disinfecting lighting device |
US11713851B2 (en) | 2015-07-30 | 2023-08-01 | Vyv, Inc. | Single diode disinfection |
AU2018200900B2 (en) * | 2017-02-08 | 2023-05-18 | Johnson & Johnson Consumer Inc. | Compositions and methods for treating skin conditions using light and polycarboxylic acids |
CN108392629A (en) * | 2017-02-08 | 2018-08-14 | 强生消费者公司 | The composition and method of skin disorder are treated with illumination and polybasic carboxylic acid |
US10596134B2 (en) * | 2017-02-08 | 2020-03-24 | Johnson & Johnson Consumer Inc. | Compositions and methods for treating skin conditions using light and polycarboxylic acids |
RU2761343C2 (en) * | 2017-02-08 | 2021-12-07 | Джонсон энд Джонсон Консьюмер Инк. | Compositions and methods for the treatment of skin pathologies using light and polycarbonate acids |
US10835627B2 (en) | 2017-12-01 | 2020-11-17 | Vital Vio, Inc. | Devices using flexible light emitting layer for creating disinfecting illuminated surface, and related method |
US11426474B2 (en) | 2017-12-01 | 2022-08-30 | Vyv, Inc. | Devices using flexible light emitting layer for creating disinfecting illuminated surface, and related methods |
US10617774B2 (en) | 2017-12-01 | 2020-04-14 | Vital Vio, Inc. | Cover with disinfecting illuminated surface |
US10309614B1 (en) | 2017-12-05 | 2019-06-04 | Vital Vivo, Inc. | Light directing element |
US11418000B2 (en) | 2018-02-26 | 2022-08-16 | Cynosure, Llc | Q-switched cavity dumped sub-nanosecond laser |
US11791603B2 (en) | 2018-02-26 | 2023-10-17 | Cynosure, LLC. | Q-switched cavity dumped sub-nanosecond laser |
US10806812B2 (en) | 2018-03-29 | 2020-10-20 | Vital Vio, Inc. | Multiple light emitter for inactivating microorganisms |
US11395858B2 (en) | 2018-03-29 | 2022-07-26 | Vyv, Inc. | Multiple light emitter for inactivating microorganisms |
US10413626B1 (en) | 2018-03-29 | 2019-09-17 | Vital Vio, Inc. | Multiple light emitter for inactivating microorganisms |
US11285335B2 (en) | 2018-10-08 | 2022-03-29 | Biohacked, Inc. | Photo-therapeutic method and apparatus |
US11639897B2 (en) | 2019-03-29 | 2023-05-02 | Vyv, Inc. | Contamination load sensing device |
US10939517B2 (en) | 2019-05-15 | 2021-03-02 | SABER Corporation | Feedback control of light emitting devices using fluorescent components and light sensors |
US11541135B2 (en) | 2019-06-28 | 2023-01-03 | Vyv, Inc. | Multiple band visible light disinfection |
US11369704B2 (en) | 2019-08-15 | 2022-06-28 | Vyv, Inc. | Devices configured to disinfect interiors |
US11717583B2 (en) | 2019-08-15 | 2023-08-08 | Vyv, Inc. | Devices configured to disinfect interiors |
US11878084B2 (en) | 2019-09-20 | 2024-01-23 | Vyv, Inc. | Disinfecting light emitting subcomponent |
Also Published As
Publication number | Publication date |
---|---|
US7066941B2 (en) | 2006-06-27 |
WO2003005883A3 (en) | 2003-10-30 |
US20040049247A1 (en) | 2004-03-11 |
WO2003005883A2 (en) | 2003-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7066941B2 (en) | Apparatus for skin treatment | |
JP7097924B2 (en) | Bio-light compositions, kits and methods | |
Spencer et al. | Indoor tanning: risks, benefits, and future trends | |
JP2022003081A (en) | Biological light composition | |
US8414880B2 (en) | PDT treatment method for cellulites and cosmetic use | |
Charakida et al. | Phototherapy in the treatment of acne vulgaris: what is its role? | |
US4874361A (en) | Method for healing damaged skin | |
Kohl et al. | Aesthetic effects of topical photodynamic therapy | |
Mills et al. | Ultraviolet phototherapy and photochemotherapy of acne vulgaris | |
US20100068161A1 (en) | Topical composition for the protection and/or treatment of radiation related skin damages | |
US5166176A (en) | Composition for healing damaged skin | |
KR20050044388A (en) | Method and apparatus for the stimulation of hair growth | |
Steinbauer et al. | Photodynamic therapy in dermatology | |
Moy et al. | Photodynamic therapy for photodamage, actinic keratosis, and acne in the cosmetic practice | |
EP0790845A1 (en) | Light therapy treatment arrangement and use thereof | |
Epstein | Photomedicine | |
US20080146667A1 (en) | Method of treatment of skin | |
JP5791903B2 (en) | Combination of light and a compound bioconvertible by lipase to improve the appearance of skin and / or hair | |
WO2001062205A2 (en) | Treatment of vitiligo | |
Colić et al. | The use of polarized light in aesthetic surgery | |
Borgia et al. | Photodynamic therapy for acne conglobata of the buttocks: Effective antiinflammatory treatment with good cosmetic outcome | |
US20050148567A1 (en) | Treatment of tattoos by photodynamic therapy | |
Moy et al. | Photodynamic Therapy for Photodamage, Actinic Keratosis, Cosmetic Practice and Acne in the | |
Dragieva et al. | Photodynamic therapy–a new treatment option for epithelial malignancies of the skin | |
Al‐Jamal et al. | Targeted phototherapy in vitiligo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |